Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0033377 (prolapse)
 11,717 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a series of 33 blepharospasm patients who had the side effect of ptosis following therapeutic botulinum toxin type A (Botox: Allergan, Inc., Irvine, CA, U.S.A.) injection, we administered 41 injections of human botulinum immune globulin (IG) following injections of the toxin to test the dosage and timing of IG injection and its effectiveness in limiting or avoiding ptosis. An IG dose of 3.2 x 10(-3) international units (IU) per unit of Botox was effective in blocking toxin effect when injected into the same tissue site within 4 hours. An IG dose of 1.6 x 10(-2) to 3.2 x 10(-2) into the levator of the eye having more frequent ptosis in 19 patients reduced the incidence of ptosis to 11%. The fellow (control) eye had a ptosis incidence of 37%. No orbital hemorrhage or other adverse effect occurred from the IG or its injection.
 ...
PMID:Preventing ptosis after botulinum treatment. 918 90

Management of the aging brow and forehead has recently evolved based on available innovative technologies. Likewise, procedure-specific indications have changed based on collective surgical experiences. No longer is the approach based solely on hair pattern or degree of brow ptosis. Patients require varying combinations of brow elevation (prior to blepharoplasty), correction of brow asymmetries, and hairline-preserving forehead elevation. Some may only require excisional or paralytic procedures of the frontalis muscle (horizontal forehead creases), corrugator supercilii muscles (vertical glabellar furrows), and procerus muscle (horizontal glabellar furrows). We present a 3-year experience using a problem-specific approach. This incorporates endoscopic technology, botulinum toxin type A purified neurotoxin complex (Botox, Allergan, Irvine, CA) intramuscular injection, and traditional procedures such as the coronal, pretrichial, midforehead, and direct browlift. Current indications, patient selection, and results are also discussed.
 ...
PMID:Contemporary management of the aging brow and forehead. 918 24

Inactivation of the orbicularis oculi muscle by chemodenervation with botulinum toxin type A (Botox, Allergan, Inc., Irvine, Calif.) as a sole procedure or in conjunction with blepharoplasty has proved to be a reliable method to improve the appearance of the periocular area. Botox has the unique and ideal characteristic in that, with repeated use, there is potential for a prolonged clinical effect with smaller dosages. In addition, if a complication does arise--while not aesthetically acceptable and potentially untoward--it is time-limited, and the anatomical area will eventually return to its pretreatment baseline status. In this study, in three cases [in more than 1000 crow's feet treatment sessions (2000 sides)] over the course of 1 year, partial lip ptosis resulting from weakening of the zygomaticus major muscle after the injection of Botox into the periocular region are reported. This article reviews suggested treatment guidelines and anatomic considerations for the periocular region to maintain injection standardization and improve the safety profile of Botox as the aesthetic indications for its use expand and the number of individuals who inject it increases.
 ...
PMID:Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. 1142 May 26

Botulotoxin A (BT) was administered to 51 patients (40 patients with essential blepharospasm, 11 patients with facial hemispasm) 299 times since December 1993 till January 2002. Total doses of 20-48 U of the preparation BOTOX (Allergan Inc.) were administered bilaterally in essential blepharospasm, doses of 12-24 U were administered unilaterally in facial hemispasm. The mean duration of therapeutic effect evaluated by the patient was 12.2 weeks (3-28 weeks) in the blepharospasm group and 13.8 weeks (7-35 weeks) in the hemispasm group. No general side effects were noted. Local complications in the blepharospasm group were observed in 8.83% (ptosis in 5.62%) and those in the facial hemispasm in 8.16% (ptosis in 2.04%) from the total number of BT administration in the respective groups. The therapeutic effect during the long-term administration was decreasing and required increasing doses of BT by more than 10%, as observed in 9 patients with essential blepharospasm (22.5%). The mean increase of BT dose required to maintain sufficient therapeutic effect was by 32% (14-66%). Two patients with the longest 8-year period of observation have not required increasing dosages above 16 U unilaterally over the last 5 years. The treatment with BT-A exerted the same effects in most cases even during long-term therapy lasting several years. The need to increase the doses of the administered BT was more frequent during the first two years of the treatment. Locally administered botulotoxin A is a safe and efficient remedy for the therapy of essential blepharospasm and facial hemispasm, the efficiency being unchanged in more than 80% of patients.
 ...
PMID:[Results of long term treatment of essential blepharospasm and facial hemispasm with botulinum toxin A]. 1501 5

Although the relative potency measured by the number of units per nanogram of the toxin is different for the three preparations (BOTOX = 20 U/ng; Dysport = 40 U/ng, and CS-BOT = 15.2 U/ng), the effective dose for CS-BOT is similar to that of BOTOX (Allergan, Irvine, CA). Despite the twofold difference in potency per nanogram, it appears that the clinically observable activity of 1 U of BOTOX is roughly equivalent to 3 U of the Dysport (Inamed, Santa Barbara, CA) product. Using quantitative analysis of regional paralysis produced by local injections into the gastrocnemius muscles of mice, prior studies estimated the potency ratio between Dysport and BOTOX to be 4.2 to 1. In a single-blind, randomized comparison study of Dysport and BOTOX in 91 patients with blepharospasm or hemifacial spasm, it was found that 4:1 dose ratio produced similar benefits. A similar 4:1 Dysport:BOTOX ratio was found to produce equivalent beneficial effects in a double-blind study in patients with blepharospasm, but the frequency of side effects, particularly of ptosis, was lower in the BOTOX group. In a study of 73 patients with cervical dystonia treated either with Dysport or BOTOX, it was concluded that a 3:1 ratio provides equivalent results. But a recent study concluded that the appropriate conversion factor between BOTOX and Dysport is less than 3. Therefore, there is some controversy about the relative potencies of the two preparations, with one study proposing that 1 unit of BOTOX corresponds to 1 unit of Dysport.
 ...
PMID:Pharmacokinetic properties of different formulations of botulinum neurotoxin type A. 1502 57

Schwartz-Jampel syndrome (SJS) is a rare congenital disorder of continuous myotonia, causing visual and eyelid problems such as blepharospasm, acquired ptosis, and blepharophimosis. We report the management of blepharospasm in two sisters with Schwartz-Jampel syndrome with application of botulinum toxin type A (BTX-A), as an alternative to the surgical treatments, such as orbicularis oculi myectomy, levator aponeurosis resection, and lateral canthopexy as described in the literature. Three consequent doses of commercially available BTX-A (Botox-Allergan, Inc. 100 u/via) were injected to orbicularis oculi muscle in two sisters with Schwartz-Jampel syndrome. At the least, the authors waited for a six-month interval to prevent development of sensitivity to BTX-A in patients. No significant improvement was observed after the injection of first dose of BTX-A, with the total dose of 25 units of BTX-A to each orbicularis oculi muscle of the eyes. The muscle tone weakened after the second dose, which was the twice as such of the first applied total dose (50 units of BTX-A to each orbicularis oculi muscle of the eyes) and significant functional and cosmetic improvements were achieved after injection of the third dose, in which the total applied dose was the same as the one applied in second dose. The blepharospasm and eyelid alterations caused by Schwartz-Jampel syndrome should be treated to provide functional and cosmetic improvements. Application of BTX-A to orbicularis oculi muscle for the treatment of blepharospasm could be considered as an alternative to levator resection, and lateral canthopexy in Schwartz-Jampel syndrome.
 ...
PMID:Results of botulinum toxin: an application to blepharospasm Schwartz-Jampel syndrome. 1687 9

Augmentation with mastopexy remains a challenge because reported complication and revision rates remain high. Previous publications are difficult to interpret because of inclusion of a broad array of mastopexy techniques and different implant styles and placements. This is a review of 100 consecutive augmentation/mastopexy patients performed by a single surgeon using a single procedure, implant style, and placement. Between January 2003 and December 2008, 100 female patients underwent primary augmentation mammoplasty with periareolar mastopexy. All patients had either grade II or grade III ptosis, or tubular deformity. All implants were Allergan style 168 (270-390 mL saline prosthesis).All patients (N = 100) were available for follow-up, an average 8.3 months postoperatively (1.5-21 months). Overall complication rate was 11%. Nonimplant-related complication rate was 6%--2 widened scars, 3 hypertrophic scars, and 1 partial nipple necrosis. Implant-related complication rate was 5%--2 deflations, 1 capsular contracture, 1 implant shifting, and 1 infection. Augmentation mammoplasty with periareolar mastopexy treats a wide variety of breast types including tubular deformity and grade II and III ptosis. Planned nipple-areolar elevation should be 4 cm or less. Vertical and horizontal skin envelope redraping is tailored for each case.
 ...
PMID:Conservative augmentation with periareolar mastopexy reduces complications and treats a variety of breast types: a 5-year retrospective review of 100 consecutive patients. 2039 15

The aim of this study was to investigate the efficacy and side effects of botulinum toxin (BTX) in the treatment of hemifacial spasm (HFS). We also focused on the divergence between different injection techniques and commercial forms. We retrospectively evaluated 470 sessions of BTX injections administered to 68 patients with HFS. The initial time of improvement, duration and degree of improvement, and frequency and duration of adverse effects were analysed. Pretarsal and preseptal injections and Botox (Allergan, Irvine, CA, USA) and Dysport (Ipsen Biopharmaceuticals, Paris, France) brands were compared in terms of efficacy and side effects, accompanied by a review of papers which reported BTX treatment of HFS. An average of 34.5 units was used per patient. The first improvement was felt after 8 days and lasted for 14.8 weeks. Patients experienced a 73.7% improvement. In 79.7% of injections, no adverse effect was reported, in 4.9% erythema, ecchymosis, and swelling in the injection area, in 3.6% facial asymmetry, in 3.4% ptosis, in 3.2% diplopia, and in 2.3% difficulty of eye closure was detected. Patients reported 75% improvement on average after 314 sessions of pretarsal injections and 72.7% improvement after 156 sessions of preseptal injections (p=0.001). The efficacy and side effects of Botox and Dysport were similar. BTX is an effective and safe treatment option for HFS. No difference was determined between Botox and Dysport, and pretarsal injection is better than preseptal injection regarding the reported degree of improvement.
 ...
PMID:Botulinum toxin injections for the treatment of hemifacial spasm over 16 years. 2610 Jan 57